LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV.

    Spadera, Lucrezia / Spadera, Maria

    Medical hypotheses

    2020  Volume 144, Page(s) 110293

    MeSH term(s) COVID-19/epidemiology ; COVID-19/immunology ; COVID-19/therapy ; DNA-Binding Proteins/genetics ; Estrogens/metabolism ; HIV Infections/epidemiology ; HIV Infections/immunology ; HIV Infections/therapy ; Humans ; Immune System ; Immunotherapy ; Italy/epidemiology ; Macrophage-Activating Factors/immunology ; Models, Theoretical ; Neoplasms/immunology ; Pandemics ; Polymorphism, Genetic ; Transcription Factors/genetics ; Vitamin D/genetics ; Vitamin D-Binding Protein/immunology ; COVID-19 Drug Treatment
    Chemical Substances DBP protein, human ; DNA-Binding Proteins ; Estrogens ; Macrophage-Activating Factors ; Transcription Factors ; Vitamin D-Binding Protein ; vitamin D-binding protein-macrophage activating factor ; Vitamin D (1406-16-2)
    Language English
    Publishing date 2020-09-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.110293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1132: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses

    Spadera, Lucrezia / Spadera, Maria

    Medical Hypotheses

    Lesson learned from HIV

    2020  Volume 144, Page(s) 110293

    Keywords General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.110293
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1132: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Adjunctive use of oral MAF is associated with no disease progression or mortality in hospitalized patients with COVID-19 pneumonia: The single-arm COral-MAF1 prospective trial.

    Spadera, Lucrezia / Lugarà, Marina / Spadera, Maria / Conticelli, Mariano / Oliva, Gabriella / Bassi, Vincenzo / Apuzzi, Valentina / Calderaro, Francesco / Fattoruso, Olimpia / Guzzi, Pietro / D'Amora, Maurizio / Catapano, Oriana / Marra, Roberta / Galdo, Maria / Zappalà, Michele / Inui, Toshio / Mette, Martin / Vitiello, Giuseppe / Corvino, Maria /
    Tortoriello, Giuseppe

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2023  Volume 169, Page(s) 115894

    Abstract: Based on a growing body of evidence that a dysregulated innate immune response mediated by monocytes/macrophages plays a key role in the pathogenesis of COVID-19, a clinical trial was conducted to investigate the therapeutic potential and safety of oral ... ...

    Abstract Based on a growing body of evidence that a dysregulated innate immune response mediated by monocytes/macrophages plays a key role in the pathogenesis of COVID-19, a clinical trial was conducted to investigate the therapeutic potential and safety of oral macrophage activating factor (MAF) plus standard of care (SoC) in the treatment of hospitalized patients with COVID-19 pneumonia. Ninety-seven hospitalized patients with confirmed COVID-19 pneumonia were treated with oral MAF and a vitamin D3 supplement, in combination with SoC, in a single-arm, open label, multicentre, phase II clinical trial. The primary outcome measure was a reduction in an intensive care unit transfer rate below 13% after MAF administration. At the end of the study, an additional propensity score matching (PSM) analysis was performed to compare the MAF group with a control group treated with SoC alone. Out of 97 patients treated with MAF, none needed care in the ICU and/or intubation with mechanical ventilation or died during hospitalization. Oxygen therapy was discontinued after a median of nine days of MAF treatment. The median length of viral shedding and hospital stay was 14 days and 18 days, respectively. After PSM, statistically significant differences were found in all of the in-hospital outcomes between the two groups. No mild to serious adverse events were recorded during the study. Notwithstanding the limitations of a single-arm study, which prevented definitive conclusions, a 21-day course of MAF treatment plus SoC was found to be safe and promising in the treatment of hospitalized adult patients with COVID-19 pneumonia. Further research will be needed to confirm these preliminary findings.
    MeSH term(s) Adult ; Humans ; COVID-19 ; Disease Progression ; Hospitalization ; Length of Stay ; Prospective Studies ; SARS-CoV-2 ; Treatment Outcome
    Language English
    Publishing date 2023-11-21
    Publishing country France
    Document type Clinical Trial ; Journal Article
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2023.115894
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.198: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Nuovi farmaci antitrombotici in patologia cardiovascolare.

    Golino, Paolo / Cimmino, Giovanni / Porchetta, Irma / Spadera, Maria / Volpe, Marianna / Calabrò, Raffaele

    Giornale italiano di cardiologia (2006)

    2006  Volume 7, Issue 2, Page(s) 109–118

    Abstract: During the past decades, a great bulk of studies have been undertaken to investigate the pathophysiologic mechanisms responsible for thrombus formation. As a consequence, different therapeutic strategies interfering at different levels of the coagulation ...

    Title translation New antithrombotic drugs in cardiovascular disease.
    Abstract During the past decades, a great bulk of studies have been undertaken to investigate the pathophysiologic mechanisms responsible for thrombus formation. As a consequence, different therapeutic strategies interfering at different levels of the coagulation process have been developed. Many of these compounds did not achieve full development, but others are presently available for the clinician. The present review paper will focus on these new therapeutic strategies developed in the last 10 years.
    MeSH term(s) Azetidines/administration & dosage ; Cardiovascular Diseases/drug therapy ; Coronary Thrombosis/drug therapy ; Drug Therapy, Combination ; Fibrinolytic Agents/pharmacology ; Fibrinolytic Agents/therapeutic use ; Glycoproteins/administration & dosage ; Humans ; Peptides/administration & dosage ; Polysaccharides/administration & dosage ; Recombinant Proteins/administration & dosage
    Chemical Substances Azetidines ; Fibrinolytic Agents ; Glycoproteins ; Peptides ; Polysaccharides ; Recombinant Proteins
    Language Italian
    Publishing date 2006-02
    Publishing country Italy
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 2272414-X
    ISSN 1972-6481 ; 1827-6806
    ISSN (online) 1972-6481
    ISSN 1827-6806
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6738: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top